Hussman Strategic Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History
Hussman Strategic Advisors, Inc.
- $407 Million
- Q2 2025
A detailed history of Hussman Strategic Advisors, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Hussman Strategic Advisors, Inc. holds 84,000 shares of HALO stock, worth $5.28 Million. This represents 1.07% of its overall portfolio holdings.
Number of Shares
84,000
Previous 73,500
14.29%
Holding current value
$5.28 Million
Previous $4.69 Million
6.84%
% of portfolio
1.07%
Previous 1.22%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
582Shares Held
122MCall Options Held
308KPut Options Held
186K-
Black Rock Inc. New York, NY17.6MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$807 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$381 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$245 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$231 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.76B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...